Catalyst Pharmaceuticals Inc (CN2 F) stock market data APIs
€19.781
0(0%)
as of December 8, 2025
Try our APIs with
free plan!
Catalyst Pharmaceuticals Inc Financial Data Overview
Price chart is built with
Anychart
Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing medicines for patients living with rare diseases in the United States. It offers Firdapse for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); Fycompa, a novel non-competitive selective antagonist at the postsynaptic ionotropic alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid glutamate receptor that is used to treat focal onset seizures, as well as tonic-clonic seizures; Ruzurgi for the treatment of pediatric LEMS patients; and AGAMREE, a corticosteroid for the treatment of duchenne muscular dystrophy. The company has license agreements with BioMarin Pharmaceutical Inc.; and a collaboration and license agreement with Endo Ventures Limited for the development and commercialization of generic Sabril tablets. Catalyst Pharmaceuticals, Inc. was founded in 2002 and is based in Coral Gables, Florida.
Prev. Close
19.781
Open
19.781
High
19.781
Low
19.781
52 wk Range
16.15-24
Market Cap
2 398 M
P/E Ratio
13.2721
Shares Outstanding
123 M
Revenue
578 M
EPS
0.11
Beta
0.682
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Catalyst Pharmaceuticals Inc data using free add-ons & libraries
Get Catalyst Pharmaceuticals Inc Fundamental Data
Catalyst Pharmaceuticals Inc Fundamental data includes:
- Net Revenue: 578 M
- EBITDA: 297 M
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2021-08-09
- EPS/Forecast: 0.1
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Catalyst Pharmaceuticals Inc News
New
Catalyst (CPRX) Up 10% Since Last Earnings Report: Can It Continue?
A month has gone by since the last earnings report for Catalyst Pharmaceutical (CPRX). Shares have added about 10% in that time frame, outperforming the S&P 500. But investors have to be wondering, w...
Catalyst Pharmaceutical (CPRX) Recently Broke Out Above the 20-Day Moving Average
From a technical perspective, Catalyst Pharmaceutical (CPRX) is looking like an interesting pick, as it just reached a key level of support. CPRX recently overtook the 20-day moving average, and this ...
Is There Still Value in Catalyst Pharmaceuticals After Its 540% Five Year Surge?
Wondering if Catalyst Pharmaceuticals is still worth buying after its huge multi year run, or if the easy money has already been made? You are not alone, and this is exactly the question we are going ...
AppLovin Stock Rides Swarm Of Setups Beyond Just Mining, Medical Names
As mining and medical stocks dominate this breakout screen, Alphabet and AppLovin stock look to keep the AI party going. Continue Reading
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
